论文部分内容阅读
目的:探讨人免疫球蛋白联合脑苷肌肽治疗重症手足口病(HFMD)的临床疗效。方法:84例重症HFMD患儿随机分为观察组与对照组各42例,观察组给予人免疫球蛋白联合脑苷肌肽治疗,对照组仅给予人免疫球蛋白治疗,比较两组患儿治疗效果。结果:观察组总有效率为95.24%,高于对照组的73.81%,两组比较差异有统计学意义(P<0.05);两组患儿神经功能评分均显著降低,且观察组低于对照组(P<0.01);观察组患儿临床症状、体征恢复时间及总住院时间均显著短于对照组(P<0.01)。结论:人免疫球蛋白联合脑苷肌肽治疗重症手足口病可在有效改善患儿的机体免疫功能、对抗病毒感染所致的多种损伤基础上进一步促进神经功能损伤的恢复,改善患儿症状体征,缩短住院时间,提高治疗效果。
Objective: To investigate the clinical efficacy of human immunoglobulin combined with cerebroside in the treatment of severe hand-foot-mouth disease (HFMD). Methods: Eighty-four children with severe HFMD were randomly divided into observation group and control group, with 42 cases in each group. The observation group received human immunoglobulin combined with cerebroside, while the control group received only human immunoglobulin. The therapeutic effect was compared between the two groups . Results: The total effective rate in the observation group was 95.24%, which was higher than that in the control group (73.81%). There was significant difference between the two groups (P <0.05). The neurological scores of the two groups were significantly lower than those of the control group (P <0.01). The clinical symptoms, signs recovery time and total hospital stay in the observation group were significantly shorter than those in the control group (P <0.01). Conclusion: Human immunoglobulin combined with cerebroside for the treatment of severe hand-foot-mouth disease can effectively improve the immune function of children and further promote the recovery of nerve function damage and improve the symptoms and signs of children based on various injuries caused by virus infection , Shorten the hospital stay, improve the treatment effect.